CA-LASERFICHE
16.4.2024 15:01:33 CEST | Business Wire | Press release
Laserfiche — the leading SaaS provider of intelligent content management and business process automation — has announced a number of channel momentum milestones as the organization marks the start of a new era of growth and technology innovation. In 2024, the company is strengthening its partner ecosystem to deliver more ways for organizations to transform the way they manage content, automate workflows and accelerate how business gets done.
“We’ve seen incredible progress across all areas of Laserfiche over the past year, including growth into emerging industries and regions, increased investment into our channel program and resources, and hiring of key leaders,” said Laserfiche CEO Karl Chan. “In 2024, we look forward to building on this momentum, continuing to strengthen our partner ecosystem and bringing even more solutions to market that empower organizations and inspire the world.”
Expanding Global Footprint
Over the past year, Laserfiche saw widespread adoption of digital transformation initiatives in all global regions, with particular growth in EMEA. Testament to this, MBS, a nearly 20-year-old Laserfiche Solution Provider that has customers in 49 countries worldwide, experienced 200% growth in the number of Laserfiche users served. For its success, MBS earned the 2024 Laserfiche International Partner of the Year Award.
“In recent years, we have seen a marked increase in the demand for digital transformation, and Laserfiche is the ideal solution,” said MBS Managing Director Rupert Leaton. “We’re proud to partner with a world-leading vendor for intelligent content management and business process automation, which stays ahead of the curve when it comes to providing innovative solutions for our customers.”
Bolstering Channel Success
In 2024, Laserfiche is building on the momentum with enhancements to its award-winning Solution Provider Program, including new product trainings, sales and marketing resources to support partners. The newly introduced Premier Partner Program increases visibility of highly qualified solution providers and helps to connect them to customers that can best leverage their business and solutions expertise.
Additional new benefits to the Laserfiche Solution Provider Program include a reimagined Winners Circle event to celebrate the top sales achievers annually; open forums for the Laserfiche sales community to share knowledge and strategy; a solution provider track at the annual Laserfiche Empower Conference; and the opportunity to participate in regular advisory councils to influence sales campaigns and resources, product roadmap and more.
Award-Winning Partner Program
“With the growing demand for information management and process automation solutions that also provide enterprise-level information governance, integration and scalability tools, Laserfiche channel partners are uniquely positioned for success,” said Vicki VanValin, vice president of sales at Laserfiche. “We are committed to leading the industry by providing our partners with innovative technology, robust resources and best-in-class service.”
In 2024, The Laserfiche Solution Provider Program earned a 5-star rating in the 2024 Partner Program Guide by CRN, a brand of The Channel Company. The rating is awarded to the companies that go above and beyond in their commitment to nurturing strong, profitable, successful channel partnerships.
Laserfiche’s employees are continually recognized across the channel for their participation and achievements. In February, three of its channel leaders were named to CRN’s 2024 Channel Chief list, including Taylor Grosso, senior director of Global Channels and Alliances, Charles Suzara, associate director – west, and Vicki VanValin, vice president of sales. The prestigious CRN Channel Chiefs list, released annually, recognizes IT vendor and distribution executives who are driving strategy and setting the channel agenda for their companies. In 2023, three others were named to CRN’s Women of the Channel list, including Jann Michishima, partner marketing manager; Nicole Moulton, senior technical trainer; and Kathleen Park, presales manager.
“From getting channel partners the resources they need to ongoing communication and collaboration, Laserfiche’s channel support is among the strongest in the industry,” said Grosso. “Our award-winning channel leadership is dedicated to enabling our partners to achieve their goals, and provide exceptional value to customer organizations around the world.”
Laserfiche will unveil additional enhancements and investments in its channel program in the coming months. To learn more about the Laserfiche Solution Provider Program and the benefits of becoming a partner, visit laserfiche.com/partners.
About Laserfiche
Laserfiche is the leading SaaS provider of intelligent content management and business process automation. Through powerful workflows, electronic forms, document management and analytics, the Laserfiche® platform accelerates how business gets done, enabling leaders to focus on growth across the enterprise.
Laserfiche pioneered the paperless office with enterprise content management. Today, Laserfiche’s cloud-first development approach incorporates innovations in machine learning and AI to enable organizations in more than 80 countries to transform into digital businesses. Customers in every industry — including government, education, financial services, healthcare and manufacturing — use Laserfiche to boost productivity, scale their business and deliver digital-first customer experiences.
Laserfiche employees in offices around the world are committed to the company’s vision of empowering customers and inspiring people to reimagine how technology can transform lives.
Connect with Laserfiche:
Laserfiche Blog | Twitter/X | LinkedIn | Facebook
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240416107538/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
